---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-084406"
form_type: "8-K"
ticker: null
cik: "0001796129"
company_name: "Vincerx Pharma, Inc."
filed_at: "2025-04-17T23:59:59+00:00"
generated_at: "2026-05-23T12:10:13.286865+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Vincerx Pharma to delist from Nasdaq, dissolve and liquidate; trading suspended Apr 23

## Summary
- Received Nasdaq delisting notice on Apr 14 due to bid price below $1 for 30 days; no compliance period available due to prior reverse stock split.
- Board unanimously approved plan of dissolution and liquidation on Apr 17, subject to stockholder approval.
- Will not appeal Nasdaq determination; intends to voluntarily delist and deregister via Form 25 (filing on/around Apr 28) and Form 15.
- Nasdaq inadvertently suspended trading on Apr 16; trading resumes Apr 21-22 before permanent suspension at open on Apr 23.
- No plans to list on another exchange; any assets remaining after creditors will be distributed to stockholders.

## SEC filing metadata
- accession: 0001193125-25-084406
- form_type: 8-K
- cik: 0001796129
- company_name: Vincerx Pharma, Inc.
- filed_at: 2025-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796129/000119312525084406/0001193125-25-084406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796129/000119312525084406/d932920d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-084406
- JSON: https://secwatch.observer/filing/0001193125-25-084406.json
- Plain text: https://secwatch.observer/filing/0001193125-25-084406.txt

## Key facts
- Listing & Compliance Notices
  Vincerx Pharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)(iv)
  source text: April 14, 2025, Vincerx Pharma, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq listing rule 5550(a)(2) because the closing bid price of the Company’s common stock for the last 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share (the “Minimum Bid Price Requirement”). Pursuant to Nasdaq listing rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Nasdaq listing rule 5810(c)(3)(A) because the Comp
  evidence_url: https://www.sec.gov/Archives/edgar/data/1796129/000119312525084406/0001193125-25-084406-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.